<DOC>
	<DOCNO>NCT02912260</DOCNO>
	<brief_summary>The primary objective study determine effect once-daily oral MGL-3196 percent change hepatic fat fraction baseline patient biopsy-proven Non-alcoholic Steatohepatitis ( NASH ) .</brief_summary>
	<brief_title>Phase 2 Study MGL-3196 Patients With Non-Alcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Inclusion Criteria . Patients meet follow criterion eligible participate study : Must willing participate study provide write informed consent ; Male female adult ≥18 year age BMI &lt; 45 kg/m^2 ; Female patient child bear potential negative serum pregnancy ( beta human chorionic gonadotropin ) test breastfeed , plan become pregnant study , agree use effective birth control ( ie , condom , diaphragm , non hormonal intrauterine device [ IUD ] , sexual abstinence [ line patient 's current lifestyle ] ) throughout study least 1 month study completion ; hormonal contraception ( estrogens stable ≥3 month ) hormonal IUDs permit used secondary birth control measure ( eg , condom ) ; OR female patient nonchild bear potential ( ie , surgically [ bilateral oophorectomy , hysterectomy , tubal ligation ] naturally sterile [ &gt; 12 consecutive month without menses ] ) ; Male patient sexual intercourse female partner child bear potential first dose study drug 1 month study completion must either surgically sterile ( confirm document azoospermia &gt; 90 day procedure ) OR agree use condom spermicide . All male patient must agree donate sperm first dose study drug 1 month study completion ; Must confirmation ≥10 % liver fat content PDFFMRI ; Biopsyproven NASH . Must prior liver biopsy within 180 day randomization fibrosis stage 1 3 NAS ≥4 least score 1 follow NAS component : Steatosis ( score 0 3 ) , Ballooning degeneration ( score 0 2 ) , Lobular inflammation ( score 0 3 ) ; Must document historical ( 3 week 6 month prior study entry ) ALT AST level consistent screen ALT AST value . Exclusion Criteria . Patients meet follow criterion exclude participation study : Note : Unless otherwise specify , repeat test may perform consultation Medical Monitor . History significant alcohol consumption period 3 consecutive month within 1 year prior screening ; Weight gain loss &gt; 5 % 6 month prior randomization &gt; 10 % 12 month prior screen ; Hyperthyroidism ; Patients thyroid replacement therapy ; Prior plan ( study period ) bariatric surgery ( eg , gastroplasty , rouxenY gastric bypass ) ; Type 1 diabetes ; Uncontrolled Type 2 diabetes define Hemoglobin A1c ≥ 9.5 % screening ( patient HbA1c ≥ 9.5 % may rescreened ) ; Use obeticholic acid , ursodeoxycholic acid ( Ursodiol® Urso® ) , high dose vitamin E ( &gt; 400 IU/day ) unless stable dose vitamin E &gt; 400 IU/day least 6 month time liver biopsy , pioglitazone within 90 day prior enrollment since screen biopsy , whichever longer ; Presence cirrhosis liver biopsy ( stage 4 fibrosis ) ; Platelet count &lt; 140,000/mm^3 ; Clinical evidence hepatic decompensation ; Evidence form chronic liver disease ; Active , serious medical disease likely life expectancy &lt; 2 year ; Participation investigational new drug trial 30 day prior randomization ; Any condition , opinion Investigator , would impede compliance , hind completion study , compromise wellbeing patient , interfere study outcome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>